投资工具 / 美股
Becton Dickinson · BDX
数据仅供参考,不构成投资建议。
投资工具 / 美股
数据仅供参考,不构成投资建议。
| 季度 | 截止日 | 申报日 | 营收 | 营收同比 g | Δg | 推导方式 |
|---|---|---|---|---|---|---|
| 2026Q2 | 2026-06-30 | 2026-08-06 | $4.98B | +5.4% | +0.2pp | 3M |
| 2026Q1 | 2026-03-31 | 2026-05-07 | $4.71B | +5.2% | +3.6pp | 3M |
| 2025Q4 | 2025-12-31 | 2026-02-09 | $5.25B | +1.6% | −51.1pp † | 3M |
| 2025Q3 | 2025-09-30 | 2026-08-06 | $8.3B | +52.7% | +58.0pp † | FY-9M |
| 2025Q2 | 2025-06-30 | 2026-08-06 | $4.73B | −5.3% | +5.9pp | 3M |
| 2025Q1 | 2025-03-31 | 2026-05-07 | $4.48B | −11.2% | −21.0pp | 3M |
| 2024Q4 | 2024-12-31 | 2026-02-09 | $5.17B | +9.8% | +2.9pp | 3M |
| 2024Q3 | 2024-09-30 | 2025-11-25 | $5.44B | +6.9% | +4.6pp | FY-9M |
口径:单季同比;Δg = 本季 g − 上季 g;按财季映射日历季度;申报日可见。† 不连续点(上年同季营收 ≤0 或 Δg 幅度超过 50pp)。 · 数据截至 2026-11-16 · 来源 SEC EDGAR XBRL
| 季度 | 截止日 | 毛利 | 销货成本 | 毛利率 | 环比 | 同比 | Δ² |
|---|---|---|---|---|---|---|---|
| 2026Q2 | 2026-06-30 | 缺口径:GrossProfit 最后申报于 2020-09-30 | $2.67B | 46.5% | +76bp | −83bp | −499bp |
| 2026Q1 | 2026-03-31 | 缺口径:GrossProfit 最后申报于 2020-09-30 | $2.56B | 45.7% | −21bp | +415bp |
| 季度 | 截止日 | 合同负债 | CL g | RPO | RPO g | 账单额 | 账单额 g | RPO 覆盖 |
|---|---|---|---|---|---|---|---|---|
| 2026Q2 | 2026-06-30 | $334M | −32.1% | 无数据 | 无数据 | $4.98B | +5.4% | 无数据 |
| 2026Q1 | 2026-03-31 | $337M | −31.9% |
| 季度 | 截止日 | OCF TTM | OCF g | CapEx TTM | CapEx g | FCF TTM | CapEx 密度 | SBC/FCF | SBC/Rev |
|---|---|---|---|---|---|---|---|---|---|
| 2026Q2 | 2026-06-30 | $3.96B | +43.5% | $753M | +10.9% | $3.2B | 3.2% | 8.8% | 1.2% |
| 2026Q1 | 2026-03-31 | $4.27B |
| 季度 | 截止日 | 存货 | 存货 g | 营收 g | 剪刀差 | DIO | DIO 同比 |
|---|---|---|---|---|---|---|---|
| 2026Q2 | 2026-06-30 | $3.32B | −16.0% | +5.4% | −21.5pp | 113.4 | −31.2 |
| 2026Q1 | 2026-03-31 | $3.36B | −9.8% | +5.2% | −15.1pp | 119.7 |
| 交易日 | 申报日 | 申报人 | 头衔 | 代码 | 股数 | 价格 | 金额 | 10b5-1 |
|---|---|---|---|---|---|---|---|---|
| 2026-11-05 | 2026-11-09 | Polen Thomas E Jr | Chairman, CEO and President | S | 2,993 | $210.00 | $628.53K |
口径:修正广度 =(近 30 日上调 − 下调)/(上调 + 下调),样本 < 3 不出;只展示衍生指标,不展示一致预期原值。 · 数据截至 2026-11-16 · 来源:Yahoo Finance / Nasdaq
未覆盖(期权覆盖为 S&P 500 期权持仓前 100 名每日、其余每周轮换)
暂无警报
口径:本股的警报事件历史(含基线);事件保留 90 天。
| +149bp |
| 2025Q4 | 2025-12-31 | 缺口径:GrossProfit 最后申报于 2020-09-30 | $2.84B | 45.9% | −267bp | +266bp | −17bp |
| 2025Q3 | 2025-09-30 | 缺口径:GrossProfit 最后申报于 2020-09-30 | $4.27B | 48.6% | +128bp | +283bp | +177bp |
| 2025Q2 | 2025-06-30 | 缺口径:GrossProfit 最后申报于 2020-09-30 | $2.49B | 47.3% | +575bp | +106bp | +519bp |
| 2025Q1 | 2025-03-31 | 缺口径:GrossProfit 最后申报于 2020-09-30 | $2.62B | 41.5% | −171bp | −413bp | −430bp |
| 2024Q4 | 2024-12-31 | 缺口径:GrossProfit 最后申报于 2020-09-30 | $2.93B | 43.2% | −250bp | +17bp | −1213bp |
| 2024Q3 | 2024-09-30 | 缺口径:GrossProfit 最后申报于 2020-09-30 | $2.95B | 45.7% | −49bp | +1230bp | +912bp |
缺口径:毛利(GrossProfit 最后申报于 2020-09-30)
口径:GM = 毛利/营收;毛利缺失时用 营收−销货成本 推导;环比/同比为基点。 · 数据截至 2026-11-16 · 来源 SEC EDGAR XBRL
| 无数据 |
| $4.59B |
| +2.7% |
| 无数据 |
| 2025Q4 | 2025-12-31 | $457M | −9.0% | 无数据 | 无数据 | $5.37B | +3.6% | 无数据 |
| 2025Q3 | 2025-09-30 | $336M | −30.3% | 无数据 | 无数据 | $8.15B | +48.9% | 无数据 |
| 2025Q2 | 2025-06-30 | $492M | +9.6% | 无数据 | 无数据 | $4.72B | −5.5% | 无数据 |
| 2025Q1 | 2025-03-31 | $495M | +12.5% | 无数据 | 无数据 | $4.47B | −11.7% | 无数据 |
| 2024Q4 | 2024-12-31 | $502M | +19.8% | 无数据 | 无数据 | $5.19B | +10.1% | 无数据 |
| 2024Q3 | 2024-09-30 | $482M | +17.0% | 无数据 | 无数据 | $5.47B | 无数据 | 无数据 |
口径:g = 同比;账单额 = 营收 + Δ合同负债(同口径);RPO 覆盖 = RPO / TTM 营收。跨口径(总额/仅流动)不比较。 合同负债口径: 总额 · 数据截至 2026-11-16 · 来源 SEC EDGAR XBRL
| +44.0% |
| $774M |
| +11.5% |
| $3.5B |
| 3.4% |
| 7.9% |
| 1.2% |
| 2025Q4 | 2025-12-31 | $3.39B | −7.8% | $763M | +6.9% | $2.63B | 3.4% | 9.8% | 1.1% |
| 2025Q3 | 2025-09-30 | $3.43B | −10.8% | $760M | +4.8% | $2.67B | 3.4% | 9.7% | 1.1% |
| 2025Q2 | 2025-06-30 | $2.76B | −30.9% | $679M | −6.1% | $2.08B | 3.4% | 11.1% | 1.2% |
| 2025Q1 | 2025-03-31 | $2.96B | −21.5% | $694M | −5.6% | $2.27B | 3.5% | 10.4% | 1.2% |
| 2024Q4 | 2024-12-31 | $3.68B | +6.8% | $714M | −8.7% | $2.97B | 3.5% | 8.6% | 1.2% |
| 2024Q3 | 2024-09-30 | $3.84B | +28.6% | $725M | −17.0% | $3.12B | 3.6% | 7.9% | 1.2% |
口径:TTM = 近四个离散单季之和;FCF = OCF − CapEx;CapEx 密度 = CapEx/营收 TTM;FCF≤0 时 SBC/FCF 不计算。 · 数据截至 2026-11-16 · 来源 SEC EDGAR XBRL
| −10.1 |
| 2025Q4 | 2025-12-31 | $4.09B | +5.8% | +1.6% | +4.2pp | 131.2 | +11.1 |
| 2025Q3 | 2025-09-30 | $3.15B | −18.1% | +52.7% | −70.7pp | 67.3 | −51.6 |
| 2025Q2 | 2025-06-30 | $3.95B | +21.3% | −5.3% | +26.6pp | 144.7 | +34.0 |
| 2025Q1 | 2025-03-31 | $3.72B | +15.3% | −11.2% | +26.5pp | 129.7 | +22.2 |
| 2024Q4 | 2024-12-31 | $3.86B | +16.8% | +9.8% | +7.0pp | 120.1 | +7.6 |
| 2024Q3 | 2024-09-30 | $3.84B | +17.4% | +6.9% | +10.5pp | 118.9 | +30.7 |
口径:剪刀差 = 存货同比 − 营收同比(pp,正值=存货增速快于营收);DIO = 存货/销货成本 × 91.25 天。 · 数据截至 2026-11-16 · 来源 SEC EDGAR XBRL
| ✓ |
| 2026-10-26 | 2026-10-27 | Feld Michael | EVP, Chief Revenue Officer | S | 76 | $198.13 | $15.06K | ✓ |
| 2026-09-28 | 2026-09-29 | Feld Michael | EVP, Chief Revenue Officer | S | 76 | $183.70 | $13.96K | ✓ |
| 2026-08-26 | 2026-08-27 | Feld Michael | EVP, Chief Revenue Officer | S | 165 | $188.49 | $31.1K | ✓ |
| 2026-08-13 | 2026-08-14 | Polen Thomas E Jr | Chairman, CEO and President | S | 4,152 | $185.00 | $768.12K | ✓ |
| 2026-08-11 | 2026-08-12 | Goette Roland | EVP and President, EMEA | S | 2,438 | $180.84 | $440.89K |
| 2026-07-27 | 2026-07-28 | Feld Michael | EVP, Chief Revenue Officer | S | 75 | $157.13 | $11.78K | ✓ |
| 2026-06-26 | 2026-06-26 | Feld Michael | EVP, Chief Revenue Officer | S | 75 | $152.80 | $11.46K | ✓ |
| 2026-06-24 | 2026-06-25 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | S | 1,100 | $145.66 | $160.23K | ✓ |
| 2026-06-10 | 2026-06-11 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | S | 1,100 | $151.48 | $166.63K | ✓ |
| 2026-06-01 | 2026-06-03 | Polen Thomas E Jr | Chairman, CEO and President | S | 2,764 | $146.35 | $404.51K | ✓ |
| 2026-05-26 | 2026-05-27 | Feld Michael | EVP, Chief Revenue Officer | S | 75 | $147.35 | $11.05K | ✓ |
| 2026-04-27 | 2026-04-28 | Feld Michael | EVP, Chief Revenue Officer | S | 74 | $151.94 | $11.24K | ✓ |
| 2026-03-26 | 2026-03-27 | Feld Michael | EVP, Chief Revenue Officer | S | 75 | $156.83 | $11.76K | ✓ |
| 2026-02-26 | 2026-02-27 | Feld Michael | EVP, Chief Revenue Officer | S | 75 | $181.84 | $13.64K | ✓ |
| 2026-02-18 | 2026-02-18 | SCOTT BERTRAM L | — | S | 953 | $182.61 | $174.03K |
| 2026-01-26 | 2026-01-28 | Feld Michael | EVP, CRO & Pres. Life Sciences | S | 75 | $202.73 | $15.2K | ✓ |
| 2026-01-15 | 2026-01-16 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | S | 600 | $209.00 | $125.4K | ✓ |
| 2026-01-15 | 2026-01-16 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | S | 1,010 | $206.54 | $208.61K | ✓ |
| 2025-12-26 | 2025-12-29 | Feld Michael | EVP, CRO & Pres. Life Sciences | S | 74 | $196.08 | $14.51K | ✓ |
| 2025-12-17 | 2025-12-17 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | S | 629 | $196.03 | $123.3K | ✓ |
| 2025-12-01 | 2025-12-02 | Feld Michael | EVP, CRO & Pres. Life Sciences | S | 75 | $193.36 | $14.5K | ✓ |
| 2025-11-07 | 2025-11-07 | SCOTT BERTRAM L | — | S | 217 | $176.58 | $38.32K |
| 2025-10-27 | 2025-10-28 | Feld Michael | EVP & President, Life Sciences | S | 57 | $186.01 | $10.6K | ✓ |
| 2025-09-26 | 2025-09-29 | Feld Michael | EVP & President, Life Sciences | S | 58 | $181.03 | $10.5K | ✓ |
| 2025-09-10 | 2025-09-11 | Fraser Claire | — | S | 917 | $187.50 | $171.94K |
| 2025-08-22 | 2025-08-26 | Feld Michael | EVP & President, Life Sciences | S | 57 | $197.99 | $11.29K | ✓ |
| 2025-08-11 | 2025-08-11 | HAYES GREGORY | — | P | 5,250 | $191.57 | $1.01M |
| 2025-08-08 | 2025-08-08 | Fraser Claire | — | S | 863 | $192.30 | $165.95K |
| 2025-07-18 | 2025-07-22 | Garrison Michael David | EVP & President, Medical | S | 1 | $181.50 | $181.5 | ✓ |
| 2025-07-18 | 2025-07-22 | Garrison Michael David | EVP & President, Medical | S | 1,184 | $180.29 | $213.46K | ✓ |
| 2025-06-02 | 2025-06-02 | Shan David | EVP and Chief ISC Officer | S | 1,166 | $171.19 | $199.61K | ✓ |
| 2025-04-09 | 2025-04-10 | Garrison Michael David | EVP & President, Medical | S | 479 | $197.28 | $94.5K | ✓ |
| 2025-03-18 | 2025-03-19 | Byrd Richard | EVP & President Interventional | S | 459 | $230.00 | $105.57K | ✓ |
| 2025-03-12 | 2025-03-13 | Byrd Richard | EVP & President Interventional | S | 1,940 | $224.91 | $436.33K | ✓ |
| 2025-02-12 | 2025-02-12 | SCOTT BERTRAM L | — | S | 700 | $227.99 | $159.59K |
| 2025-02-10 | 2025-02-10 | Henderson Jeffrey William | — | P | 1,500 | $233.62 | $350.43K |
| 2025-01-21 | 2025-01-22 | Shan David | EVP and Chief ISC Officer | S | 500 | $240.00 | $120K | ✓ |
| 2025-01-21 | 2025-01-22 | Neal Shana Carol | EVP and Chief People Officer | S | 787 | $240.00 | $188.88K | ✓ |
| 2025-01-17 | 2025-01-21 | Garrison Michael David | EVP & President, Medical | S | 597 | $236.51 | $141.2K | ✓ |
口径:Form 4/4A 公开市场买入(P)与卖出(S),申报人为董事或高管;汇总与集群为近 365 天,明细为最近 40 笔。 · 数据截至 2026-11-16 · 来源:SEC EDGAR Form 4
口径:SI 来自 FINRA(双周结算);SI% 分母 = SEC 封面总股本;借券费为 IBKR 报价(非全市场);卖空占比 = 当日卖空量/总成交量。 · 数据截至 SI 2026-10-30 · Reg SHO 2026-11-16 · 借券 2026-11-11 · 沿用上一版 · 来源:FINRA、IBKR、iBorrowDesk